Immix Biopharma, Inc. financial data

Symbol
IMMX on Nasdaq
Location
11400 West Olympic Blvd., Suite 200, Los Angeles, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 170 % -67.3%
Debt-to-equity 35 % +106%
Return On Equity -264 % -157%
Return On Assets -120 % -48.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.6M shares +22.1%
Common Stock, Shares, Outstanding 33M shares +20.2%
Entity Public Float 32.4M USD +16%
Common Stock, Value, Issued 3.31K USD +20.1%
Weighted Average Number of Shares Outstanding, Basic 31.9M shares +8.5%
Weighted Average Number of Shares Outstanding, Diluted 31.9M shares +8.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.9M USD -8.55%
General and Administrative Expense 12.1M USD +20.9%
Operating Income (Loss) -24.1M USD -4.28%
Nonoperating Income (Expense) 525K USD -50.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -23.5M USD -6.92%
Income Tax Expense (Benefit) 37.2K USD -2.86%
Net Income (Loss) Attributable to Parent -23.6M USD -7.64%
Earnings Per Share, Basic 0 USD/shares +10.6%
Earnings Per Share, Diluted 0 USD/shares +10.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.9M USD -19%
Other Assets, Current 133K USD +264%
Assets, Current 16.6M USD -27.1%
Property, Plant and Equipment, Net 2.36M USD +74%
Operating Lease, Right-of-Use Asset 1.01M USD -0.47%
Other Assets, Noncurrent 20.4K USD 0%
Assets 20.1M USD -20.1%
Accounts Payable, Current 7.05M USD +114%
Employee-related Liabilities, Current 438K USD +121%
Liabilities, Current 10.9M USD +65.3%
Operating Lease, Liability, Noncurrent 965K USD -5.97%
Liabilities 11.8M USD +55.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 62.5K USD -67.5%
Retained Earnings (Accumulated Deficit) -93.8M USD -33.6%
Stockholders' Equity Attributable to Parent 13.3M USD -19.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 8.26M USD -52.9%
Liabilities and Equity 20.1M USD -20.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.69M USD +56%
Net Cash Provided by (Used in) Financing Activities 15.9M USD +13312%
Net Cash Provided by (Used in) Investing Activities -67.7K USD +77.6%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 33.1M shares +20.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.76M USD -115%
Deferred Tax Assets, Valuation Allowance 15.8M USD +107%
Operating Lease, Liability 1.11M USD +1.59%
Depreciation 38.2K USD +1168%
Payments to Acquire Property, Plant, and Equipment 67.7K USD -77.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.7M USD -41.4%
Lessee, Operating Lease, Liability, to be Paid 1.51M USD -3.99%
Property, Plant and Equipment, Gross 64.5K USD 0%
Operating Lease, Liability, Current 141K USD +125%
Lessee, Operating Lease, Liability, to be Paid, Year Two 158K USD +3.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 219K USD +48.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 399K USD -16.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 164K USD +3.5%
Deferred Tax Assets, Operating Loss Carryforwards 6.71M USD +64.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 164K USD
Additional Paid in Capital 102M USD +16.4%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 590K USD +167%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%